The ScleroTest Project promoted by BIOITHAS has received funding from European Union´s Horizon 2020 research and innovation programme under grant agreement No 867463.

The ScleroTest project proposed by Bioithas SL for the development of a “Diagnostic kit with capacity to predict the response to treatment by a subject suffering from Multiple Sclerosis” has been selected by the European Commission for the granting of Phase I of the Program of Research and Innovation Horizon 2020 of the SME Instrument.

The funding received by Bioithas S.L will be used to develop and execute a feasibility study to verify the concept of disruptive innovation of the technology used for the development of the project.

The main objective of this project is to tackle the serious problem posed by the lack of predictive biomarkers of response to treatment for the chronic inflammatory disease of the central nervous system with the highest prevalence of socioeconomic impact in the world: Multiple Sclerosis. In addition, through the development of this project will be available to hospitals, clinics, medical centers and laboratories the first rapid diagnostic kit based on the technique of  q-PCR, non-invasive and capable of monitoring the immunomodulatory profile of the patients and their response to treatment.